NASDAQ:MNOV

MediciNova - MNOV Stock Forecast, Price & News

$2.48

-0.01 (-0.40%)

(As of 08/15/2022 12:00 AM ET)

Add

Compare

Today's Range: $2.41
▼
$2.48
50-Day Range: $2.28
▼
$2.62
52-Week Range: $2.09
▼
$4.65

Volume: 27,218 shs
Average Volume: 60,616 shs
Market Capitalization: $121.63 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

MediciNova MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 141.9% Upside
$6.00 Price Target
Short Interest: Bearish
2.42% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.22
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.21) to ($0.37) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

844th out of 1,125 stocks

Pharmaceutical Preparations Industry

428th out of 554 stocks

3.5

Analyst's Opinion

Consensus Rating
MediciNova has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, MediciNova has a forecasted upside of 141.9% from its current price of $2.48.
Amount of Analyst Coverage
MediciNova has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.42% of the float of MediciNova has been sold short.
Short Interest Ratio / Days to Cover
MediciNova has a short interest ratio ("days to cover") of 42.6, which indicates bearish sentiment.
Change versus previous month
Short interest in MediciNova has recently decreased by 4.17%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
MediciNova does not currently pay a dividend.
Dividend Growth
MediciNova does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MNOV.

4.0

News and Social Media Coverage

News Sentiment
MediciNova has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for MediciNova this week, compared to 2 articles on an average week.
Search Interest
1 people have searched for MNOV on MarketBeat in the last 30 days.
MarketBeat Follows
1 people have added MediciNova to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MediciNova insiders have not sold or bought any company stock.
Percentage Held by Insiders
15.80% of the stock of MediciNova is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 15.57% of the stock of MediciNova is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for MediciNova are expected to decrease in the coming year, from ($0.21) to ($0.37) per share.
Price to Book Value per Share Ratio
MediciNova has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About MediciNova (NASDAQ:MNOV) Stock

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

MediciNova Stock Up 2.0 %

MNOV opened at $2.49 on Monday. MediciNova has a twelve month low of $2.09 and a twelve month high of $4.65. The company has a 50-day simple moving average of $2.46 and a 200 day simple moving average of $2.52.

MediciNova (NASDAQ:MNOV - Get Rating) last announced its quarterly earnings results on Thursday, May 12th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.02. Sell-side analysts anticipate that MediciNova will post -0.21 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of MediciNova in a research report on Friday. They issued a "hold" rating on the stock.

Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

MNOV Stock News Headlines

August 15, 2022 | americanbankingnews.com

MediciNova (NASDAQ:MNOV) Coverage Initiated at StockNews.com

August 9, 2022 | globenewswire.com

MediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation - GlobeNewswire

August 9, 2022 | finance.yahoo.com

August 8, 2022 | americanbankingnews.com

MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com

August 5, 2022 | americanbankingnews.com

MediciNova (NASDAQ:MNOV) & AstraZeneca (NASDAQ:AZN) Financial Review

July 27, 2022 | globenewswire.com

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea - GlobeNewswire

July 27, 2022 | finance.yahoo.com

MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea

July 27, 2022 | finance.yahoo.com

MediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia - Yahoo Finance

July 26, 2022 | benzinga.com

Recap Of Tuesday’s Biotech Catalysts - End of The Day Summary - Benzinga - Benzinga

July 26, 2022 | benzinga.com

MediciNova Announces Initiation Of A Phase 2 Trial Of MN-001 In NAFLD With Type 2 Diabetes Mellitus And H - Benzinga

July 26, 2022 | finance.yahoo.com

MediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia

July 22, 2022 | seekingalpha.com

MediciNova begins study of parenteral formulation of MN-166 - Seeking Alpha

July 22, 2022 | finance.yahoo.com

MediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast) - Yahoo Finance

July 21, 2022 | globenewswire.com

MediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast) - GlobeNewswire

July 21, 2022 | finance.yahoo.com

MediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)

June 30, 2022 | uk.investing.com

The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial By Benzinga - Investing.com UK

June 30, 2022 | seekingalpha.com

MediciNova announces extension of BARDA contract for Ibudilast development - Seeking Alpha

June 30, 2022 | finance.yahoo.com

MediciNova Announces Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

June 29, 2022 | benzinga.com

MediciNova Announces Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasur - Benzinga

June 24, 2022 | seekingalpha.com

CytomX stock rises after BMO Capital starts with Outperform rating - Seeking Alpha

June 23, 2022 | finance.yahoo.com

MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan - Yahoo Finance

June 22, 2022 | globenewswire.com

MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan - GlobeNewswire

June 22, 2022 | finance.yahoo.com

MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan

June 13, 2022 | finance.yahoo.com

MNOV: Positive Results for MN-166 (Ibudilast) in Patients at Risk of Acute Respiratory Distress Syndrome…

June 10, 2022 | finance.yahoo.com

Genmab to Participate in a Fireside Chat at the Goldman Sachs 43rd Annual Global Healthcare Conference - Yahoo Finance

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

MNOV Company Calendar

Last Earnings: 10/26/2020
Today: 8/15/2022
Next Earnings (Estimated): 11/10/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MNOV
CUSIP: N/A
CIK: 1226616
Web: medicinova.com
Phone: (858) 373-1500
Fax: 858-404-0048
Employees: 11
Year Founded: 2000

Price Target and Rating

Average Stock Price Forecast: $6.00
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +141.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,130,000.00
Net Margins: N/A
Pretax Margin: -33,961.38%
Return on Equity: -15.99%
Return on Assets: -15.19%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.17
Quick Ratio: 17.17

Sales & Book Value

Annual Sales: $4.04 million
Price / Sales: 30.11
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.71 per share
Price / Book: 1.45

Miscellaneous

Outstanding Shares: 49,043,000
Free Float: 41,297,000
Market Cap: $121.63 million
Optionable: Optionable
Beta: 0.97

Social Links

Key Executives

Dr. Yuichi Iwaki M.D. (Age 72)
Ph.D., Co-Founder, Pres, CEO & Exec. Director
Comp: $777.7k
Dr. Kazuko Matsuda M.D. (Age 56)
M.P.H., MPH, Ph.D., Chief Medical Officer & Director
Comp: $564.13k
Mr. Jason J. Kruger CPA (Age 45)
CFO & Principal Financial Officer
Dr. David H. Crean M.B.A. (Age 57)
Ph.D., Chief Bus. Officer
Mr. John O'Neil CPA
Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MNOV Stock - Frequently Asked Questions

Should I buy or sell MediciNova stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MNOV shares.
View MNOV analyst ratings or view top-rated stocks.
What is MediciNova's stock price forecast for 2022?: 1 brokers have issued 1 year price objectives for MediciNova's shares. Their MNOV share price forecasts range from $6.00 to $6.00. On average, they predict the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 141.9% from the stock's current price.
View analysts price targets for MNOV or view top-rated stocks among Wall Street analysts.
How have MNOV shares performed in 2022?: MediciNova's stock was trading at $2.68 at the beginning of the year. Since then, MNOV shares have decreased by 7.5% and is now trading at $2.48.
View the best growth stocks for 2022 here.
When is MediciNova's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our MNOV earnings forecast.
How were MediciNova's earnings last quarter?: MediciNova, Inc. (NASDAQ:MNOV) released its quarterly earnings results on Monday, October, 26th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.04.
What other stocks do shareholders of MediciNova own?: Based on aggregate information from My MarketBeat watchlists, some companies that other MediciNova investors own include Dynavax Technologies (DVAX), VBI Vaccines (VBIV), OPKO Health (OPK), Iovance Biotherapeutics (IOVA), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Trevena (TRVN), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX) and CymaBay Therapeutics (CBAY).

What is MediciNova's stock symbol?: MediciNova trades on the NASDAQ under the ticker symbol "MNOV."
Who are MediciNova's major shareholders?: MediciNova's stock is owned by a variety of retail and institutional investors. Top institutional investors include Millennium Management LLC (0.73%), JPMorgan Chase & Co. (0.60%), UBS Group AG (0.38%), Renaissance Technologies LLC (0.33%), Bailard Inc. (0.04%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Hideki Nagao, Kazuko Matsuda and Yuichi Iwaki.
View institutional ownership trends.
How do I buy shares of MediciNova?: Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is MediciNova's stock price today?: One share of MNOV stock can currently be purchased for approximately $2.48.
How much money does MediciNova make?: MediciNova (NASDAQ:MNOV) has a market capitalization of $121.63 million and generates $4.04 million in revenue each year.
When was MediciNova founded?: MediciNova was founded in 2000.
How can I contact MediciNova?: MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The official website for the company is medicinova.com. The biopharmaceutical company can be reached via phone at (858) 373-1500, via email at info@medicinova.com, or via fax at 858-404-0048.

This page (NASDAQ:MNOV) was last updated on 8/16/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MediciNova - MNOV Stock Forecast, Price & News

MediciNova MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month